Admescope has acquired MetaSafe AB

OULU, FINLAND - Admescope Ltd, a pre-clinical ADME-Tox service provider today announced the acquisition of MetaSafe AB, a company specialised in the field of metabolic biotransformation research.

MetaSafe, based in Södertälje, Sweden, is a contract research organisation working with small, midsize and large pharmaceutical companies in the area of drug biotransformation/metabolism. MetaSafe is especially focusing on clinical phase drug metabolism studies from safety perspective, but also provides services for preclinical stage of drug development.

Admescope, having the headquarters and laboratories in Oulu, Finland, will continue to operate MetaSafe’s business in Södertälje. This acquisition will strengthen Admescope’s drug metabolism services further to clinical phase projects, as well as gives the benefit of having another high-quality laboratory facility.

Dr Ari Tolonen, CEO of Admescope said: “We are excited about the acquisition, and warmly welcoming MetaSafe’s experienced experts as a part of the Admescope team. Due to the excellent synergy between the companies´ service portfolios and operative models, this acquisition will add value for both MetaSafe’s and Admescope’s customers, as together we create a more comprehensive service offering with strengths from the both companies”.

Dr Johanna Haglund, CEO of MetaSafe continued: “At MetaSafe we are very pleased to see a future as an integrated part of Admescope. Together we can position our global business even better, more sustainably and more efficiently - to the advantage of our customers and business partners. The merger will create a unique ADME CRO, providing complete ADME services to our customers. MetaSafe’s and Admescope’s services are highly complementary, and in the future we will be in a position to provide our customers with a comprehensive offering from a single source for everything relating to ADME services in order to ensure early and late lead candidate optimization”.